| Name (Synonyms) | Correlation | |
|---|---|---|
| drug35 | AMY-101 Wiki | 1.00 |
| drug1483 | WFI 5% glucose Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.13 |
| D055371 | Acute Lung Injury NIH | 0.12 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.12 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.10 |
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Description: mortality rates in two groups will be compared
Measure: mortality Time: 4 months